Bots Inc (BTZI): Everyone that orders a VITACIG will orde...

Everyone that orders a VITACIG will order many

shortorlong · 2014-04-16T00:42:29.5800000Z

Everyone that orders a VITACIG will order many more after trying them. These really are that good. I can't wait to start my day with Energize, get a pick me up after lunch with a Refresh, and cap my day off in my spa or bed with my favorite, Relax. These are amazing and all you have to do is puff on it. Amazing, timeless design. I will hold my many MCIG shares and load up on even more VITACIG shares. I am not pumping, I am just blown away by this product at this price point. $2 a piece is a steal. I would not be surprised if a big company tried to buy us out. I bet everyone here will be surprised by the first quarter numbers. I know that I will be good for at least 50+ for me and many, many more from referrals. One thing I wonder is if future production VITACIGS will have the stock symbol on them when the company starts to trade (like mCig does). MCIG/VITACIG Long

Play Episode

25min

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

North Bay Resources reports high-grade copper results from Feb 2025 exploration at Copper Island

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to unveil the latest exploration results from the company’s Copper Island Project, following a comprehensive rock sampling program conducted in February 2025. The program targeted eight outcrops within the Pomeroy 1-3, Beaver, and Copper Bell zones, yielding highly promising results. According to Lazerson, assay results revealed copper concentrations as high as 5.69%, along with silver reaching 1 ounce per ton and vanadium at 0.22%. The average assay values stood at 4.6% copper, 0.5 ounces per ton silver, and 0.9% vanadium, further underscoring the project’s potential. Additionally, metallurgical testing indicated that copper mineralization exists in oxide form up to 74.4%, with average oxide copper content of 40.3%, 42.1%, and 58.4% across three different leach tests. This is a crucial finding, as copper in oxide form is typically associated with lower processing costs and higher recovery rates, enhancing the project's economic viability. The Pomeroy 3-4 Zone, one of the most significant areas of interest, exhibits mineralization over a strike length of approximately 750 feet—making it the largest of the numerous copper-silver zones identified to date. The mineralization is associated with a northwest-to-north-trending sequence of amygdaloidal basaltic flows, with key east-west to east-northeast-south-southwest cross-cutting fault and fracture zones contributing to the structural complexity. Multiple parallel mineralized zones have also been identified, further expanding the project's exploration potential. With these encouraging results, North Bay Resources continues to advance its exploration efforts, positioning the Copper Island Project as a compelling opportunity in the copper and critical minerals sector. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #

Proactive - Interviews for investors

Charbone Hydrogen partners with ABB to develop 15 green hydrogen facilities in North America

Charbone Hydrogen Chief Operations Officer Daniel Charette joined Steve Darling from Proactive to announce the signing of a Memorandum of Understanding with ABB, marking a significant step toward scaling green hydrogen production across North America. The agreement outlines plans to develop up to 15 modular and scalable hydrogen production facilities over the next five years, targeting industries that currently rely on grey hydrogen, such as steelmaking and heavy industrial processes. Under the MoU, ABB will serve as Charbone’s preferred supplier for modular electrical substations (eHouses), providing design, engineering, fabrication, and testing. ABB will also assist in standardizing core engineering systems across Charbone’s project portfolio to enhance energy efficiency and reliability. Depending on project needs, ABB may also take on automation, electrification, and telecom roles. One of the first projects in this collaboration is Charbone’s flagship Sorel-Tracy facility, located near Montreal, Québec. Expected to be connected to the Hydro-Québec grid by Q2 2025, the facility will utilize hydroelectric power to run green hydrogen electrolyzers, creating a scalable model for future sites. Following this, Charbone’s next project will be in the greater Detroit area, a key hub for automotive manufacturing. This initiative aligns with the Government of Québec’s Green Hydrogen and Bioenergy Strategy, which aims to reduce petroleum consumption by nearly 1 billion liters annually by 2030. By promoting green hydrogen adoption in key industrial sectors, the province could cut greenhouse gas emissions by 4 megatons of CO₂ per year—equivalent to removing 1.2 million gasoline-powered vehicles from the roads. With its partnership with ABB and government-backed initiatives supporting clean energy, Charbone Hydrogen is positioning itself as a leader in North America’s transition to sustainable hydrogen solutions. #proactiveinvestors #charbonehydrogencorportion #tsxv #ch #ot

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Followers	32
Posts	4650
Boards Moderated	0
Alias Born	02/19/2013

Volume:	223,346
Day Range:	0.0048 - 0.0059
Bid:	0.0052
Ask:	0.007
Last Trade Time:	3:43:13 PM EDT
Total Trades:	26

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BTZI Detailed Quote

Recent BTZI News

More BTZI News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BTZI News

Go Ad-Free